PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

triazolam Side Effects

The reactions most often reported to the FDA for triazolam (also sold as Halcion), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

8,521
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of triazolam come from 8,521 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 8,521 reports to the FDA Adverse Event Reporting System (FAERS) for triazolam (Halcion): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

8,521

Reports Mentioning Death

1,218

14.3% of reports — not proof the medicine caused the death

Hospitalizations

3,668

43.0% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

DRUG ABUSE
519
SOPOR
402
NAUSEA
352
OVERDOSE
350
FALL
315
INSOMNIA
303
PYREXIA
302
SUICIDE ATTEMPT
302
DIARRHOEA
290
DIZZINESS
282
SOMNOLENCE
280
MALAISE
267
HEADACHE
262
LOSS OF CONSCIOUSNESS
260
INTENTIONAL OVERDOSE
255
FATIGUE
251
DRUG INTERACTION
250
TOXICITY TO VARIOUS AGENTS
238
VOMITING
237

Who Reports Side Effects

Gender Distribution

Female 4,618 (58%)
Male 3,312 (42%)
Unknown 30

Age Distribution

0-17 167 (3%)
18-44 1,184 (19%)
45-64 1,850 (29%)
65-74 1,371 (22%)
75+ 1,727 (27%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 1,218 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
COMPLETED SUICIDE 222
DEATH 200
TOXICITY TO VARIOUS AGENTS 135
PNEUMONIA 80
OVERDOSE 76
CARDIO-RESPIRATORY ARREST 46
DIARRHOEA 46
INTERSTITIAL LUNG DISEASE 46
RESPIRATORY FAILURE 46
CARDIAC ARREST 42
CARDIAC FAILURE 41
NAUSEA 40
PYREXIA 40
VOMITING 40
DRUG ABUSE 37
DEPRESSED LEVEL OF CONSCIOUSNESS 34
DRUG INTERACTION 34
MALIGNANT NEOPLASM PROGRESSION 33
FALL 32
DYSPNOEA 31

Reactions in Hospitalization Reports

Top reactions in 3,668 reports where hospitalization was an outcome.

Reaction Reports
DRUG ABUSE 321
SOPOR 286
PYREXIA 197
FALL 194
OVERDOSE 193
SUICIDE ATTEMPT 182
INTENTIONAL OVERDOSE 167
PNEUMONIA 162
NAUSEA 153
DYSPNOEA 146
LOSS OF CONSCIOUSNESS 144
DRUG INTERACTION 140
VOMITING 138
DIARRHOEA 134
MALAISE 119
INTENTIONAL SELF-INJURY 116
SOMNOLENCE 115
DEHYDRATION 114
DIZZINESS 114
ASTHENIA 107

Compare triazolam vs eszopiclone →

What the FAERS Data Reveals About triazolam Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 8,521 voluntary reports linked to triazolam and its brand equivalents (Halcion), spanning 2004 through 2025. Of those, 1,218 (14.3%) listed death as an outcome and 3,668 (43.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 58% were female and 42% male; age distribution skews toward 45-64, with 1,850 reports in that bracket. The single most reported reaction is drug abuse with 519 submissions, followed by sopor and nausea.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.